IRIS
RUGGIERO, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.503
NA - Nord America 4.299
EU - Europa 3.245
SA - Sud America 622
Continente sconosciuto - Info sul continente non disponibili 172
AF - Africa 143
OC - Oceania 4
Totale 13.988
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.122
SG - Singapore 2.549
RU - Federazione Russa 1.659
CN - Cina 1.068
VN - Vietnam 772
IT - Italia 529
BR - Brasile 503
DE - Germania 375
HK - Hong Kong 371
IN - India 178
FR - Francia 167
BD - Bangladesh 147
KR - Corea 116
NL - Olanda 115
FI - Finlandia 109
GB - Regno Unito 98
JP - Giappone 98
CA - Canada 79
MX - Messico 46
AR - Argentina 45
CI - Costa d'Avorio 38
ZA - Sudafrica 37
UA - Ucraina 35
PL - Polonia 29
SE - Svezia 27
IQ - Iraq 25
IE - Irlanda 23
PK - Pakistan 23
TH - Thailandia 19
PH - Filippine 18
TR - Turchia 18
ID - Indonesia 17
EC - Ecuador 15
BG - Bulgaria 14
KE - Kenya 14
CL - Cile 13
ES - Italia 12
JM - Giamaica 12
CO - Colombia 11
MA - Marocco 11
VE - Venezuela 11
EG - Egitto 10
MY - Malesia 10
AT - Austria 9
JO - Giordania 9
PY - Paraguay 9
CR - Costa Rica 8
SA - Arabia Saudita 8
TW - Taiwan 8
PE - Perù 7
RS - Serbia 7
TT - Trinidad e Tobago 7
UZ - Uzbekistan 6
DZ - Algeria 5
IL - Israele 5
LT - Lituania 5
OM - Oman 5
PT - Portogallo 5
TN - Tunisia 5
UY - Uruguay 5
CZ - Repubblica Ceca 4
ET - Etiopia 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BB - Barbados 3
BE - Belgio 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
EE - Estonia 3
HN - Honduras 3
HR - Croazia 3
LB - Libano 3
MK - Macedonia 3
NP - Nepal 3
PA - Panama 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AF - Afghanistan, Repubblica islamica di 2
AU - Australia 2
BS - Bahamas 2
BY - Bielorussia 2
GT - Guatemala 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
NI - Nicaragua 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
SV - El Salvador 2
TJ - Tagikistan 2
TZ - Tanzania 2
ZW - Zimbabwe 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CH - Svizzera 1
Totale 13.796
Salva come PNG Salva come JPEG
Città #
Singapore 1.289
San Jose 939
Hefei 479
Ashburn 463
Moscow 445
Hong Kong 358
Santa Clara 310
Beijing 252
Ho Chi Minh City 213
Chandler 191
Hanoi 181
Munich 131
Council Bluffs 122
Lauterbourg 117
The Dalles 113
Seoul 95
Los Angeles 93
Kochi 85
Amsterdam 83
Tokyo 77
Helsinki 71
Naples 66
Boston 64
Redondo Beach 58
Milan 56
Buffalo 55
Lawrence 55
New York 53
Rome 51
São Paulo 48
Dallas 45
Millbury 43
Napoli 40
Phoenix 38
Seattle 38
Des Moines 35
Houston 34
Da Nang 32
Haiphong 30
Chicago 29
Atlanta 28
Düsseldorf 26
Frankfurt am Main 24
Montreal 24
Krefeld 23
Rio de Janeiro 23
Toronto 23
Chennai 22
Brooklyn 21
Washington 21
Mexico City 20
Falkenstein 19
Lappeenranta 19
Orem 19
Warsaw 18
London 17
Johannesburg 16
Wilmington 16
Dublin 15
Turin 15
Fairfield 14
Nuremberg 14
San Francisco 14
Woodbridge 14
Biên Hòa 12
Brasília 12
Sofia 12
Stockholm 12
Turku 12
Denver 11
Mumbai 11
Nairobi 11
Poplar 11
Florence 10
Guangzhou 10
Kingston 10
Pune 10
Amman 9
Arezzo 9
Cagliari 9
Kronberg 9
Menlo Park 9
Baghdad 8
Belo Horizonte 8
Boardman 8
Campinas 8
Portsmouth 8
Xi'an 8
Ankara 7
Bengaluru 7
Can Tho 7
Guayaquil 7
Hải Dương 7
Karlsruhe 7
Magenta 7
Manchester 7
New Delhi 7
Phủ Lý 7
Quận Một 7
Rochdale 7
Totale 7.763
Salva come PNG Salva come JPEG
Nome #
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose 294
Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection 256
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence 175
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study 163
The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: A short report of the clinical data 163
Persistent candidiasis infection during anti‐ IL ‐17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review 161
Management of Psoriasis Patients with Serious Infectious Diseases 157
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 154
QuantiFERON TB‐gold conversion rate among psoriasis patients under biologics: a 9‐year retrospective study 142
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 142
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 141
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 139
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears 139
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 137
Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role? 137
Corrigendum: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab (Clin Cosmet Investig Dermatol. (2023), 16, (3503–3507), 10.2147/CCID.S447123) 136
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report 133
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 132
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 131
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 130
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 129
Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa 129
Impact of current anti-psoriatic systemic treatments on male and female fertility: what the endocrinologist needs to know 128
QuantiFERON TB-gold conversion is not uncommon in psoriasis patients under anti-TNF-α 127
Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo 126
Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency 125
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 124
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge 124
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis 124
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation 123
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 123
A case of linear psoriasis in a young patient with Down syndrome and review of the literature 122
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 122
Giant nodular melanoma of the nose in a 78‐year old female refusing complete excision 121
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 121
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 121
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 121
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 120
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 120
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 120
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 120
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 118
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study 118
A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: should treatment be discontinued? 118
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 117
A case of severe psoriasis in a 84-year old women successfully treated with ixekizumab 117
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review 114
Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre 113
A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab 112
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 111
JAK Inhibitors in Psoriatic Disease 110
The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre 110
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 110
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 109
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 109
Etanercept for pediatric acrodermatitis continua of Hallopeau: a case report and literature review 109
An atypical ear nodule 109
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 109
A case of erythrodermic psoriasis successfully treated with guselkumab 107
A case of erythrodermic psoriasis successfully treated with apremilast 107
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? 106
Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome 106
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding 106
Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS 105
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 105
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 104
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 104
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 103
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 103
Comment on 'Morphoea following COVID-19 vaccination' 102
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 102
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 101
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 101
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 99
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 99
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis 99
Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic 99
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus 99
Chronic cutaneous ulcers management in dermatologic department during COVID-19 era 99
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al 98
Dupilumab associated inflammatory arthritis: a literature review 97
Reply to ‘Impact of the French COVID ‐19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al 96
Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' 96
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 96
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars 95
The Past, the Present and the Future of Teledermatology: A Narrative Review 94
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire 92
ChatGPT and Dermatology: friends or foes? 92
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment 92
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 91
Safety of dupilumab in atopic patients during COVID-19 outbreak 91
Cutaneous Squamous Cell Carcinoma: From Diagnosis to Follow-Up 89
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 88
Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic 87
Hair Aging and Hair Disorders in Elderly Patients 84
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 83
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al 82
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series 82
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 81
New frontiers in personalized medicine in psoriasis 79
Totale 11.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.633
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022318 0 0 3 13 22 23 2 20 4 44 45 142
2022/2023684 59 43 35 24 68 70 57 80 91 81 56 20
2023/2024755 32 97 83 67 42 70 21 74 23 27 133 86
2024/20254.215 211 226 30 34 123 301 419 321 340 468 1.419 323
2025/20267.185 842 769 738 679 1.062 286 849 390 799 366 207 198
2026/2027603 155 278 170 0 0 0 0 0 0 0 0 0
Totale 13.988